Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NCC to build 219 rental apartments in Skellefteå, Sweden

NCC has signed an agreement with Skebo to construct 219 rental apartments at Anderstorpsgården in Skellefteå. The project is a turnkey contract with an order value of approximately SEK 320 million. Map over Anderstorpsgården, Skellefteå NCC’s assignment includes the new production of rental apartments in varying sizes distributed between tower blocks, low-rise buildings and row houses. Project planning will commence in spring 2024 and construction will start in autumn 2024. The neighborhood will be ready for occupancy in late 2026 or early 2027. “Demand remains strong for

Vestas – Q1 2024 conference call

Vestas Wind Systems A/S, Aarhus,Investor News, 29 April 2024 Vestas expects to disclose our Interim Financial Report, First Quarter 2024 on 2 May 2024. On the day of the release, Vestas will host a conference call, in which our CEO and CFO will present the results via an audiocast, which can be followed live or replayed. The meeting will be held in English. Time2 May 2024 at 10.00 am CEST (09.00 am BST)   AudiocastTo livestream or replay the presentation, go to Audiocast link . Q&AAt the end of

Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director

LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces the appointment of Dr. Lisa Ford as Clinical Laboratory Director.    As Clinical Laboratory Director, Dr. Ford will lead lab operations as well as research and development of Immunovia’s next-generation test. Her primary responsibilities will be staffing, developing, and overseeing the laboratory team; quality assurance and regulatory compliance; and facilitating collaboration and communication with external partners,

Two acquisitions in Finland contribute positively

The first quarter: January – March ·Net sales amounted to 326 MSEK (326) ·Order intake increased by 44 percent to 352 MSEK (245) ·Order backlog increased by 12 percent to 1,392 MSEK (1,241) ·Adjusted operating profit (EBITA) amounted to 16 MSEK (28) ·Operating profit (EBITA) amounted to 13 MSEK (23) ·Net profit after tax amounted to 2 MSEK (14) ·Earnings per share amounted to 0.10 SEK (0.63) ·Operating cash flow amounted to 18 MSEK (-11) Events during the quarter and since the end of the quarter ·January 22 Balco Group

Sectra and Leica Biosystems first in the world to gain FDA clearance to utilize DICOM images for pathology diagnostics

Linköping, Sweden – April 29, 2024 – International medical imaging IT and Cybersecurity company Sectra’s  (STO: SECT B) digital pathology solution together with Leica Biosystems, Imaging, Inc.’s Aperio GT 450 DX have received a 510(k) clearance by the US Food & Drug Administration (FDA). This is the first time an FDA clearance within digital pathology allows the use of DICOM images for pathology diagnostics, which marks a significant step towards standardization in this field.Sectra received its first FDA clearance during the pandemic, in 2020. The pandemic made the

Peab develops New Bodø Airport

Peab has been commissioned to develop New Bodø Airport as the project moves from development to implementation. The customer is Avinor and the contract is worth NOK 3.3 billion.The project comprises the construction of a new runway, taxiways and parking spaces for aircraft. Preparatory work has already been carried out in the area such as removal of vegetation, demolition of old infrastructure and blasting. "This is a historic contract and the largest Peab has received in Norway. I would like to thank Avinor for entrusting us and our close cooperation in the first phase of the project.

Securitas AB to publish the Interim Report January-March 2024 on May 8, 2024

Securitas AB will publish the Interim Report January-March 2024 on Wednesday May 8, 2024, at 8.00 a.m. (CEST).8.00 a.m. (CEST) Report releaseThe report will be sent as a press release from Cision (www.cision.se) and will automatically be published on www.securitas.com when released.  9.00 a.m. (CEST) Presentation slides availableFor presentation slides, follow the linkwww.securitas.com/en/investors/financial-reports-and-presentations  9.30 a.m. (CEST) Telephone conference and audio castAnalysts and media are invited to participate in a telephone conference at 9.30 a.m.

Immunovia streamlines lab operations with move to Research Triangle Park, North Carolina

LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces that the company will move its lab and U.S. headquarters to Research Triangle Park in North Carolina in May 2024.   The move to Research Triangle Park follows Immunovia’s successful model development study, announced on April 22, 2024 , and the successful

Result of Extraordinary General Meeting

Monday, 29 April 2024 KR1 plc (“KR1” or the “Company”) Result of Extraordinary General Meeting KR1 plc (KR1:ASE), a leading digital asset investment company, is pleased to announce that the resolution authorising KR1 to make market purchases of up to 14.99 per cent. of the Company’s issued ordinary share capital (as set out in the announcement of the Company dated 11 April 2024) was duly passed on a poll at the Extraordinary General Meeting of the Company held today. The results of the poll were as follows: +------------+----------+-----+-------+-------+----------+---------

Scandi Standard –First quarter presentation

Scandi Standard will publish its report for the first quarter of 2024 on Friday, 3 May 2024, at 07.30 CET.     Conference call at 08.30 CET The company will host a conference call for the financial community at 08.30 CET on the same day. The conference call will be hosted by Jonas Tunestål, CEO, and Fredrik Sylwan, CFO.    Dial-in numbers:United Kingdom (toll free): +44 800 358 1035  United Kingdom: +44 20 3936 2999 Sweden: +46 10 884 80 16USA (toll free): +1 855 979 6654USA: +1 646 787 9445All other places 

Eklund Foundation for Odontological Research and Education opens for applications of up to €250,000

Researchers within dentistry will soon be able to apply for grants of up to €250,000, which is the total sum allocated by the Eklund Foundation in 2024. The application portal will be open 1-31 May, welcoming applicants from all parts of the world in all fields of dentistry.Both experimental and clinical studies within all fields of dentistry are accepted, but the foundation will prioritise projects that can be related to periodontology, implantology, or cariology. Researchers may apply for funding for a project in its entirety or for part of a project.   Even though the application

poLight ASA: Approval and Publication of Supplemental Prospectus

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Reference is made to the stock exchange announcement by poLight ASA (the "Company" or "poLight") on 24 April 2024 regarding the publication of its audited consolidated financial statements as at, and for the year ended, 31 December 2023 (the "2023 Financial Statements"), and to the stock

BioStock: BioInvent selected to present at ASCO in Chicago

BioInvent has been selected to present two posters at the American Society for Clinical Oncology Annual Congress (ASCO 2024) in Chicago from May 31 to June 4. The presentations will focus on data from the company’s clinical studies with the lead drug candidates BI-1808 and BI-1206, both in phase I/IIa development in combination with MSD’s Keytruda. BI-1808 is also evaluated as single agent, which will also be included in the presentation.Read the article at biostock.se: https://www.biostock.se/en/2024/04/bioinvent-selected-to-present-at-asco-in-chicago/ This is a press release from

No updates on the Optomed Aurora AEYE FDA clearance process

Optomed Plc Stock Exchange Release 29 April 2024 at 13:20, Helsinki No updates on the Optomed Aurora AEYE FDA clearance process Optomed is together with its partner AEYE Health in the process of obtaining a clearance for the AI fundus camera Optomed Aurora AEYE.   At this stage, Optomed does not have any new information regarding the FDA clearance process. Optomed will update market as new information becomes available.   Optomed Plc Further enquiries Juho Himberg, CEO, juho.himberg@optomed.com       Optomed in Brief  Optomed is a Finnish medical

Teesside University students creating AI controlled self-driving car

Students from Teesside University are helping to develop an artificial intelligence (AI) controlled self-driving car, with testing sessions already taking place on campus.Led by Dr Alexander Ellin in the University’s School of Computing, Engineering & Digital Technologies, the team of students and staff are creating the AI controlled car as a test vehicle to help students compete in the renowned IMECHE engineering competition Formula Student. The Formula Student competition, held each year at legendary motor racing circuit Silverstone, is Europe's best known educational engineering

Section 430(2b) statement

29 April 2024   Moonpig Group plc Section 430(2B) Companies Act 2006 Statement Moonpig Group plc (the “Company”) announced on 26 April 2024 that Simon Davidson had resigned as a director of the Company with effect from 25 April 2024.  Under the Relationship Agreement between the Company and Exponent Private Equity LLP (“Exponent”) Simon’s fees as Exponent’s Nominee Director are paid directly to Exponent and will be paid up to and including the date of termination of 25 April 2024. No other remuneration payment will be made by the Company to Simon or to Exponent after Simon

Vattenfall's Annual General Meeting 2024

Vattenfall's Annual General Meeting 2024Vattenfall’s owner was represented at the AGM voting by Gustaf Hygrell at the Ministry of Finance. Annual General Meeting decisions: Adoption of balance sheet and income statement The AGM adopted the income and balance sheet for Vattenfall AB and the Vattenfall Group. Dividend The AGM decided on a dividend distribution of SEK 4 000 000 000 to the owner of the parent company for 2023. Discharge of liability The AGM decided to discharge the members of the board and the CEO from liability. Renumeration report and guidelines for

Thomas Magnussen appointed as Country Manager, Norway

Thomas Magnussen appointed as Country Manager, Norway as of May 1, 2024. He succeeds Trond Wiker, who has been appointed in another role in iLOQ. Before joining iLOQ, Thomas worked in a National and International sales role for Caverion Norge AS. He has a strong background in the security and locking industry in Norway and the Nordics. “I am honored to be a part of the iLOQ family and very excited to take on the role of Country Manager. After many years on the integrator side, I really look forward to bringing all this experience into the growth potential for iLOQ. And,

Nokian Tyres plc Interim Report January–March 2024: Building the new Nokian Tyres on track in a challenging environment

Nokian Tyres plc Interim Report January–March 2024, April 29, 2024 at 1:00 p.m. EEST   This release is a summary of Nokian Tyres’ Interim Report January–March 2024. The complete report is attached to this release. It is also available on the company’s website at www.nokiantyres.com/company/investors/.   January–March 2024  · Net sales were EUR 236.6 million (January–March 2023: 236.4). With comparable currencies, net sales increased by 1.4%. · Segments operating profit was EUR -15.1 million (-14.1). Operating profit was EUR -26.2 million (-18.8). EUR -11.1 million (-4.7)

Aker Carbon Capture ASA: Minutes of Annual General Meeting

The 2024 Annual General Meeting of Aker Carbon Capture ASA was held today as a digital meeting with online participation.All resolutions were made in accordance with the proposals set out in the meeting notice. Minutes of the meeting are attached and available on https://akercarboncapture.com/investors/general-meetings/. The articles of association were amended in accordance with the proposal. The number of board members was reduced to three, and the general meeting re-elected Kristian Monsen Røkke as the Chair of the Board of Directors, and Karl Erik Kjelstad as new deputy. ENDS

United Bankers Plc’s directed share issues to employees and tied agents and the related matching share plans

  United Bankers Plc STOCK EXCHANGE RELEASE 29 April 2024 at 12:45 EEST   United Bankers Plc’s directed share issues to employees and tied agents and the related matching share plans The Board of Directors of United Bankers Plc has today resolved to organise an employee share issue, offering new shares in the Company for subscription by the employees and management (including Managing Directors) of the United Bankers Group (the ”Employee Share Issue”). Furthermore, the Board of Directors resolved to organise a directed share issue to the tied agents of the United

Tobii publishes 2023 Annual and Sustainability Report

Tobii’s Annual Report and Sustainability Report for 2023 is as of today available on the company’s website.The Annual and Sustainability Report in Swedish as well as an English translation are available in PDF format at: https://corporate.tobii.com/investors. The Swedish version is also available in European Single Electronic Format (ESEF). For more information, please contact: Carolina Strömlid, Head of Investor Relations, Tobii AB, +46 (0)70 880 71 73, email: carolina.stromlid@tobii.com   This information is information that Tobii AB is obliged to make public pursuant to

Invitation to the presentation of the Q1 2024 results on Tuesday 7 May 2024 at 10:00 (CET)

Nordic Mining hereby invites you to the presentation of the results for the first quarter of 2024 and company update on Tuesday 7 May 2024 at 10:00 (CET). The presentation will be held digitally. The interim report and the presentation will be published at the Oslo Stock Exchange and on Nordic Mining's webpage (www.nordicmining.com) in advance of the presentation. The presentation and Q&A session will be held in English and transferred via webcast. You will have the opportunity to post questions online throughout the webcast session. The webcast will be available on: https://channel.

Medivir brings the Q1 webcast forward to 10 a.m. on April 30

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company will host the Q1 Quarterly Results webcast tomorrow, April 30, at 10 a.m. CET. The webcast is brought forward as Nasdaq Stockholm closes earlier.       For additional information, please contactMagnus Christensen, CFO, Medivir ABTelephone: +46 8 5468 3100E-mail: magnus.christensen@medivir.com         About Medivir Medivir develops innovative drugs with a focus

There are no items matching the current filter
There are no more items matching the current filter
Back to top